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Summary Attachment of poly(ethylene glycol) (PEG) to proteins can greatly alter their pharmacological
properties, including extending the plasma half-life and reducing immunogenicity, both of which are poten-
tially beneficial to tumour targeting. IgG, F(ab')2 and Fab' fragments of the anti-CEA antibody A5B7 were
chemically modified with PEG (Mr 5,000), labelled with 1251 and their pharmacokinetics compared with the
unmodified forms in the LS174T colonic xenograft in nude mice. PEG modification of the intact antibody had
little effect on biodistribution, although tumour localisation was slightly reduced. In contrast, similar
modification of F(ab')2 and Fab'A5B7 significantly prolonged plasma half-life and increased radioantibody
accumulation in the tumour and to a lesser extent in normal tissues, but reduced tissue to blood ratios. Prior
to modification, Fab' A5B7 (Mr 50,000) cleared more rapidly from the circulation than F(ab')2 (Mr 100,000),
but after PEG attachment their biodistributions converged, while the tumour to blood ratios were reduced and
resembled that of the intact antibody. The enhanced tumour accumulation, reduced normal tissue to blood
ratios and potentially reduced immunogenicity of fragments after PEG attachment may therefore prove
superior to either unmodified fragments or intact antibody for antibody-targeted therapy, although the
increased plasma half-life may necessitate the use of a clearance mechanism.
Radiolabelled antibodies against carcinoembryonic antigen
(CEA) have been employed for imaging and therapy of col-
orectal carcinomas in both animal models (Buchegger et al.,
1990; Pedley et al., 1991) and clinical studies (DeNardo et al.,
1988; Begent et al., 1989; Begent & Pedley, 1990), but dosage
is limited by the large proportion of antibody remaining in the
circulation. This is of particular concern in the case of
radioimmunotherapy (RIT), multiple doses of which are often
required for effective treatment. The result can be both
damage to normal tissues from the high circulating levels of
radiation and the development of a human anti-mouse anti-
body response (HAMA), which will lower the therapeutic
effect by the formation of rapidly clearing immune complexes,
and may also cause anaphylaxis (Ledermann et al., 1988).
The more rapid circulatory clearance and reduced
immunogenicity of antibody fragments, both resulting from
the lack of Fc binding moieties, plus their potential for
greater tumour penetration because of reduced size, make
them an attractive alternative to intact antibodies for RIT.
However, they do have the disadvantage of lower absolute
levels of accumulation in, and more rapid removal from, the
tumour (Buchegger et al., 1990; Pedley et al., 1993).
The covalent attachment of poly(ethylene glycol) (PEG) to
proteins can greatly alter their pharmacological properties.
These include an extended plasma half-life, reduced
immunogenicity and antigenicity, increased solubility and
resistance to proteolysis (Nucci et al., 1991). By selecting the
coupling agent and the molecular weight of the PEG em-
ployed, a protein-PEG molecule can be custom designed for
augmentation of its biological activity. It has been shown
that PEG substitution of a F(ab')2 fragment of an antibody
against colorectal carcinoma reduces blood clearance and
increases tumour uptake in a xenograft model (Kitamura et
al., 1991), but no comparative investigation of the intact IgG,
F(ab')2 and Fab fragments of an antibody, with and without
PEG modification, has yet been reported.
We have previously compared the therapeutic effect pro-
duced by '31I-labelled intact IgG and F(ab')2 fragments of the
anti-CEA antibody A5B7 in a colonic xenograft model
(Pedley et al., 1993). We were therefore interested in investi-
gating the effect of PEG attachment on the biodistribution of
the Fab', F(ab')2 and intact forms of A5B7, and to see
whether this modification would produce a molecule with the
combined benefits of both fragments and intact antibody for
clinical use.
Materials and methods
Antibodies
A5B7 is a murine monoclonal anti-CEA antibody (Pedley et
al., 1987), which has been used clinically for localisation and
therapy trials in our department (Ledermann et al., 1988).
Preparation ofF(ab')2 A5B7 Bromelain (Boehringer Mann-
heim) was activated by incubating with 50mM cysteine at
37°C for 30 min, followed by desalting on a Sephadex G-25
column (Pharmacia, PD-10). A5B7 was then digested at
5 mg ml-' with freshly activated bromelain in 0.1 M sodium
acetate buffer pH 5.5 containing 3 mM EDTA at 37°C with
an antibody-enzyme ratio of 50:1. The digest was moni-
tored by high-performance liquid chromatography (HPLC)
gel filtration and when complete (at approximately 30 min)
the pH was adjusted to 6 and the bromelain removed by
ion-exchange chromatography using a column of S-Seph-
arose (Pharmacia) run in 0.1 M sodium acetate buffer pH 6
and eluted with 0.5 M sodium chloride in the same buffer.
Final F(ab')2 purification was carried out by gel filtration
using a 2 m column of Sephacryl S-200HR (Pharmacia).
Purity of the F(ab')2 preparation was analysed by HPLC gel
filtration and SDS-PAGE and found to be greater than
95%.
Preparation of Fab'A5B7 F(ab')2 prepared as above was
used to produce monomeric Fab' by reduction and alkyla-
tion. F(ab')2 was concentrated to 5 mg ml-' and buffer
exchanged into 0.1 M sodium bicarbonate buffer pH 7.8 con-
taining 2mM DTPA. The F(ab')2 was then incubated with
5 mM P-mercaptoethylamine (Sigma) at 37°C for 30 min and
an excess of N-ethylmaleimide (Sigma) was added to alkylate
the liberated hinge thiols. Fab' was desalted into 0.1 M
sodium acetate pH 6.0 and any remaining F(ab')2 removed
by preparative HPLC gel filtration using a DuPont Zorbax
GF-250XL column run in 0.2 M phosphate buffer pH 7.0.
Purity was again assessed by gel filtration HPLC and
SDS-PAGE and no F(ab')2 could be detected.
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Poly(ethylene glycol) conjugation The strategy for conjuga-
tion of PEG to antibody molecules was to produce a malei-
mide-containing derivative of PEG and conjugate this to
thiols on the protein introduced by the use of 2-imino-
thiolane (Traut's reagent). Methoxypolyoxyethylene amine
(Sigma) was dissolved in 0.1 M sodium phosphate buffer
pH 7.0 and incubated with 3-maleimidopropionic acid N-
hydroxysuccinimide ester (1.2 excess) at 37°C for 1 h. The
reaction was followed by spotting an aliquot of the reaction
mixture onto a thin-layer chromatography (TLC) plate (Kie-
selgel 60) and developing with ninhydrin. The reaction was
considered complete when there was no purple coloration
remaining (amine reaction with ninhydrin). The mixture was
then desalted into water (Millipore Milli-Q SP) and
lyophilised. The PEG-maleimide produced was presented as
a white solid (yield 91%).
The antibody or antibody fragment was thiolated with
2-iminothiolane to give two thiols per antibody molecule as
described previously (Turner et al., 1994). The number of
thiols introduced was checked by titration with dithiodi-
pyridine, also as previously described (Turner et al., 1994).
PEG-maleimide was added to freshly thiolated antibody or
antibody fragment at a 5-fold molar excess over thiol concen-
tration and incubated for 1 h at 37°C. The conjugates were
then desalted into PBS for iodination and further analysis.
The number of PEG molecules added per antibody molecule
was determined by titration of free thiols before and after
addition of the PEG-maleimide reagent. Control incubations
with no maleimide added demonstrated that loss of thiols by
oxidation or other possible mechanisms was negligible.
Antigen binding analysis The ability of intact A5B7 and
A5B7 fragments to bind to the antigen before and after PEG
modification was tested using a direct binding enzyme-linked
immunosorbent assay (ELISA). Plates were coated with
0.25 tig per well of purified CEA. Serial dilutions of samples
were made in sample conjugate buffer [0.1 M Tris-HCI
pH 7.0, 0.1 M sodium chloride, 0.2% (v/v) Tween 20 and
0.2% (w/v) casein]. A 100 LI volume of each diluted sample
was added per well to the washed coated plates and
incubated for 1 h at room temperature with gentle agitation.
Plates were washed and 100y1 of a 1:5,000 dilution of goat
anti-human F(ab')2 linked to horseradish peroxidase was
added to each well. After 1 h incubation, the plates were
washed again and 100 tLI of substrate buffer (0.1 M sodium
citrate pH 6.0 containing 0.1 mg ml-I tetramethylbenzidine
(TMB) and 0.005% (v/v) hydrogen peroxide] was added to
each well. After approximately 5 min the reaction was ter-
minated by the addition of 1.5 M sulphuric acid. The optical
density was determined at 450 nm for each well by measure-
ment in a Dynatech MR600 plate reader.
Radiolabelling All antibodies were radiolabelled with 125I by
the chloramine T method. The ratio of antibody to isotope
ranged from 1 to 1.7:1 for the unmodified antibodies (mean
antibody dose 8 fig), and from 2.2 to 3.5:1 for the PEG-
modified antibodies (mean antibody dose 9Itg).
Animal studies
Xenograft The human colon adenocarcinoma cell line
LS174T (Tom et al., 1976) was used to develop a xenograft
model in the flanks of nude (nu/nu) mice. Subsequent passag-
ing was carried out by subcutaneous implantation of small
tumour pieces (approximately 1 mm3), and experiments com-
menced when the tumours were between 0.5 and 1.0 cm3. The
tumour is a moderately differentiated CEA-producing adeno-
carcinoma with small glandular acini, which secretes no
measurable CEA into the circulation (Pedley et al., 1993). All
mice used were female, 2-3 months old and weighed between
20 and 25 g.
Antibody biodistribution The tissue localisation of intact,
F(ab')2 and Fab' fragments ofA5B7 were compared with and
without PEG modification. For all preparations the antibody
was administered intravenously into the tail vein. At selected
time points over 6 days, four mice from each group were
bled and the following organs removed for activity assess-
ment on the gamma counter (Pharmacia, 1470 Wizard): liver,
kidney, lung, spleen, colon, muscle and tumour. Results were
expressed as percentage injected dose per gram of tissue (%
inj. dose g-'). Animals were given food and water ad libitum,
the water containing 0.1% potassium iodide to prevent
thyroid uptake of iodide.
Results
The biodistributions of Fab', F(ab')2 and intact A5B7, with
and without PEG modification, were compared over a period
of 6 days. Data for 48 h post antibody are not included in
the figures because similarity with those presented for 24 h,
but are given in the tumour to blood ratios (Table I).
Intact A5B7
Figure 1 shows the biodistribution of intact A5B7, with and
without PEG modification, at selected time points over a
period of 6 days. At 3 h post antibody injection there was
evidence of higher levels of blood activity for PEG-A5B7
antibody compared with the control, and this was still pre-
sent at 24 h. After 6 days, however, there was no significant
difference between the levels of antibody remaining in the
blood for the two groups. The tumour showed a trend in the
opposite direction, with slightly reduced accumulation of
PEG-radioantibody in spite of the higher blood levels found
for this group. Normal tissues remained similar for both
groups throughout the period investigated. Because the
attachment of PEG to the intact antibody had only a slight
effect on biodistribution, the tumour to blood ratios
remained similar for the two groups (Table I). However, the
slightly raised circulating levels and reduced tumour levels
produced after PEG attachment resulted in a superior
localisation index for the unmodified antibody at all time
points studied.
F(ab')2 A5B7 Figure 2 shows the biodistribution of parent
and PEG-F(ab')2 A5B7 fragments over the same 6 day
period. In this case PEG modification dramatically altered
the circulating levels of antibody at all time points studied,
giving 24.7% inj. dose g-' compared with 11.4% for the
parent fragment at 3 h, 8.1% vs 0.8% at 24 h and 0.31% vs
0.01% at 144h respectively. This was accompanied by cor-
respondingly higher radioantibody levels in the tumour and
all normal tissues examined. The PEG-F(ab')2 showed slight-
ly increased tumour localisation when compared with the
control group by 3 h after antibody administration, and this
differential became more marked with time. By 24 h the
corresponding values were 17.8% inj. dose g-' for the
modified antibody and 10.7% for the parent fragment, and
by 144 h they were 2.8% and 1% respectively.
In spite of the significant increase in tumour accumulation
found for the PEG-F(ab')2 A5B7, the concomitantly raised
blood levels produced inferior tumour-blood ratios when
compared with the parent fragment (Table I).
Table I Tumour to blood ratios of intact, F(ab')2 and Fab A5B7,
with and without PEG modification, at selected time points after
antibody administration
Time post antibody injection (h)
Antibody 3 24 48 144
Intact A5B7 0.7 3.2 3.5 4.7
PEG-A5B7 0.4 2.0 2.9 3.8
F(ab')2 A5B7 0.7 14.0 29.6 89.7
PEG-F(ab')2 0.4 2.2 3.7 8.8
A5B7
Fab A5B7 0.9 11.9 19.0 27.4
PEG-Fab A5B7 0.4 1.6 2.5 5.51128 R.B. PEDLEY et al.
Fab' A5B7 Figure 3 shows the comparative biodistribution
of PEG-Fab' and parent Fab' A5B7. The Fab' fragments
apparently showed the most rapid clearance of all the
antibody forms tested, giving the lowest blood levels
observed for all time points. The differential between cir-
culating levels of PEG-Fab' and Fab' was also the greatest,
being 20.6% vs 4.5% at 3 h, 1.5% vs 0.1% at 24 h and 0.5%
vs 0.008% at 6 days. This was reflected in comparative
tumour levels, which were 9.2% vs 4.1% at 3 h, 10.5 vs 1.5%
at 24 h and 2.7% vs 0.17% at 6 days. Normal tissues were
also higher as a direct result of prolonged circulation of the
modified antibody. Although the parent Fab' and F(ab')2
A5B7 fragments had very different clearance patterns, after
modification with PEG the activity levels in normal tissues
and tumour showed great similarity (Figures 2 and 3).
As with the F(ab')2 groups, the increase in both tumour
and circulating antibody levels resulted in inferior
30-
20
10
24 h
03
C
0
10
c .
c
U
0~
03
@3
0
0
la
.
c
0
0~
tumour-blood ratios for the PEG-Fab' when compared with
the parent fragment (Table I).
Discussion
The aim of this study was to investigate whether PEG
modification of the murine anti-CEA antibody A5B7 and its
fragments would improve their potential for tumour localisa-
tion and therapy.
All three forms of the antibody molecule were successfully
conjugated to two PEG molecules. The PEG modified intact
antibody showed no reduction in CEA binding activity, while
binding of the F(ab')2 and the Fab' fragments was reduced
by approximately 12% and 20% respectively when compared
with the parent forms. Higher levels of PEG modification
gave a greater extension of circulatory half-life, but this was
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Figure 1 Tissue distribution over time of intact A5B7, with or
without PEG modification, in the LS174T colonic xenograft
model in nude mice. Results are expressed as percentage of
injected antibody dose perg-' of tissue, and are the means of
four mice. Vertical bars indicate s.d. _, Intact A5B7; M,
PEG-A5B7.
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Figure 2 Tissue distribution over time of F(ab')2 A5B7, with or
without PEG modification, in the LSI74T colonic xenograft
model in nude mice. Results are expressed as percentage of
antibody dose perg-' of tissue, and are the means of four mice.
Vertical bars indicate s.d. _, F(ab')2 A5B7; M,
PEG-F(ab')2 A5B7.
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Figure 3 Tissue distribution over time of Fab A5B7, with or
without PEG modification, in the LS174T colonic xenograft
model in nude mice. Results are expressed as percentage of
antibody dose per g-' of tissue, and are the means of four mice.
Vertical bars indicate s.d. , Fab A5B7; M, PEG-Fab
A5B7.
accompanied by a further loss in antigen-binding activity,
which had a detrimental effect on tumour localisation (data
not shown).
PEG modification of intact A5B7 had little effect on
biodistribution. Although the blood activity levels were
slightly increased over the first 24 h when compared with the
parent form (34.0% vs 25.3% at 3 h and 20.2% vs 14.0% at
24 h), this did not result in higher antibody levels in other
normal tissues (Figure 1), and normal tissue to blood ratios
remained very similar for the two groups throughout the
experiment (data not shown). The tumour, however, showed
a trend of decreased accumulation of intact A5B7 after PEG
modification in spite of the raised blood levels, and inferior
tumour to blood levels were found for all time points studied
(Table I). Kitamura et al. (1991) found that the circulatory
time of an intact anti-colon carcinoma antibody in a xeno-
graft model was doubled after attachment of PEG, while
tumour localisation was reduced. Levels in normal organs
were either reduced (liver and spleen) or the same (lung and
kidney) as found for the parent antibody. They suggest that
reduced tumour levels may be caused by a blockade of
transcapillary filtration owing to the higher molecular weight
after PEG conjugation. It is thought that PEG-modified
proteins have higher molecular weights than would be
predicted by direct calculation of the number of PEG
molecules attached (in the present case an additional 10 kDa
per antibody molecule), probably because ofhydration of the
attached polymer (Knauf et al., 1988).
Conjugation of PEG to the F(ab')2 A5B7 approximately
doubled the circulatory activity when compared with the
unmodified fragments (Figure 2), resulting in higher
accumulation in both tumour and normal tissues. This is in
agreement with Kitamura et al. (1991), and is at least partly a
reflection of reduced kidney filtration, although steric hind-
rance of non-specific binding and reduced proteolysis prob-
ably play a role. Renal clearance rate may be correlated with
the molecular size of a protein, decreasing with increased size
up to a threshold around Mr 70,000, which is thought to be
the permeability threshold of the kidney glomerular filtration
system. The fact that the differential between circulatory
clearance of PEG-modified and parent intact A5B7 (Mr
150,000) was small in comparison with that found for the
fragments is probably because the intact antibody was
already above the size for renal filtration before polymer
attachment. It is not clear how F(ab')2 fragments, Mr
100,000, are filtered by the kidney, and it is possible that a
proportion is dissociated into the constituent Fab' fragments.
However, it is known that glomerular selectivity is based not
only on molecular size, but also on shape and charge of the
protein, and the attachment of PEG to the lysine side chains
of the protein does appear to increase the negative charge of
the molecule (Knauf et al., 1988).
Parent Fab' A5B7 had the lowest blood activity levels of
the three forms of antibody studied (Figure 3), in agreement
with rapid kidney clearance for a molecule that size (Mr
50,000). After PEG modification, however, the size of the
Fab' molecule appeared to be raised above renal filtration
limit, and the antibody behaved almost identically to the
PEG-F(ab')2 pharmacokinetically, with higher activity levels
in tumour, blood and other normal tissues (Figures 2 and
3).
The increased circulatory half-life of antibody after PEG
attachment, accompanied by higher tumour levels in the case
of fragments, produced very similar tumour to blood ratios
for all three forms of A5B7 at all time points studied, while
the parent forms exhibited wide variations (Table I). The
localisation index was always inferior to that of the
unmodified antibody, and there was also little increase in the
tumour to blood ratio with time. This was particularly true
for F(ab')2 A5B7, PEG modification of which reduced the
tumour to blood ratio from 30:1 to 3.7:1 at 48 h and from
89.7 to 8.8:1 at 144h after antibody delivery.
Although normal tissues also showed a higher accumula-
tion of Fab' and F(ab')2 A5B7 after PEG modification,
antibody specificity was improved because tissue to blood
ratios were consistently around half those found for the
parent fragments (data not shown). Kitamura et al. (1991)
report lower levels of intact and F(ab')2 anti-colon carcinoma
antibody in normal tissues after PEG attachment, and sug-
gest this may be caused by steric hindrance of non-specific
antibody uptake. Other situations may also benefit, as we
have found that PEG modification of a chimeric Fab' frag-
ment of A5B7 overcame the problem of high relative kidney
accumulation, reducing the kidney to blood ratio from 20:1
to 1:1 a 24 h after administration (in preparation). Thus
PEG conjugation enhanced tumour uptake while improving
target specificity of the antibody.
One of the disadvantages of employing F(ab')2 or Fab'
fragments rather than the intact antibody for RIT is reduced
tumour localisation. After PEG modification the tumour
levels were significantly raised, though they never reached
- - -
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those achieved by the intact A5B7 (Figures 1, 2 and 3).
However, fragments do show deeper tumour penetration,
thereby enhancing the range of cell kill at an early stage after
administration when the intact antibody is still accumulated
around the blood vessels (Boxer et al., 1994). Although we
have still to determine whether PEG-modified fragments
show altered tumour penetration, their use for therapy thus
has the potential for increasing the tumour dose when com-
pared with parent fragments, while possibly also improving
the range of tumour cell kill over intact antibody. Circulating
activity after administration of PEG-modified fragments was
significantly lower than that of unmodified intact antibody,
although a method of clearance such as a second antibody or
an avidin-biotin system may be required to reduce potential
damage to normal tissues if repeat dose therapy is used
(Marshall et al., 1994). There appears to be little advantage
in using the Fab' fragments in preference to the F(ab')2 after
PEG modification because, while normal tissues remain
similar over time, the F(ab')2 A5B7 shows higher tumour
localisation (Figures 2 and 3; Table I).
A further advantage of PEG modification of proteins is the
potential for reducing immunogenicity, possibly by shielding
antigenic determinants with the immunologically inert
polymer, and possibly by avoidance of reticuloendothelial
cells (Francis et al., 1991). Kitamura et al. (1991) have shown
that PEG attachment to an intact murine monoclonal anti-
body against human colon cancer reduces the HAMA re-
sponse significantly when compared with the parent intact
antibody. This is very important for RIT, as successful treat-
ment requires repeated doses of antibody and an immune
response would significantly reduce the effective radiation
dose to the tumour (Ledermann et al., 1988).
In conclusion, we have demonstrated that PEG
modification of an intact anti-CEA antibody has little effect
on its subsequent biodistribution and clearance. In com-
parison, similar modification of its Fab' and F(ab')2
fragments dramatically increased the plasma half-life, pro-
ducing enhanced tumour accumulation and reduced normal
tissue to blood ratios, although tumour to blood ratios were
also reduced. The possibility of further reducing fragment
immunogenicity by PEG attachment should therefore make
them superior to either the parent forms or the intact
antibody for all types of antibody-directed therapy. In addi-
tion, the feasibility of custom-designed PEG-antibody
molecules for augmentation of biological activity, such as
site-directed attachment and labile bonds, make this a useful
tool for enhancing therapeutic potential.
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